This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1716-EFinanceIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Starting at €8.20
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1715-EFinanceThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Starting at €8.20
-
Genzyme and Relational Investors: Science and Business Collide? - Teaching Note
Eades, Kenneth M.; Matos, PedroTeaching Note DARDEN-F-1660TN-EFinanceTeaching note for product F-1660Starting at €0.00
-
La Diversificación en el negocio farmacéutico
Olaya Estefan, E.; Calero Castro, M.Case IIST-ASNI-18Decision AnalysisUn responsable de farmacia que, con gran iniciativa, está diversificando su negocio con productos y servicios relacionados y aprovechando sinergias. Se le presenta una nueva oportunidad y debe definir los elementos del modelo de negocio y reflexiona sobre lo oportuno ya que sus dos empresas anteriores le exigen esfuerzo y tiempo de forma importante.Starting at €8.20
-
Tauten. Inversión y desinversión en nuevos negocios
Olaya Estefan, E.; Calero Castro, M.Case IIST-ASNI-17Decision AnalysisUn empresario que recibe la propuesta de venta de una cartera de clientes complementaria a su negocio principal y unos años después la vende a un empleado. El caso permite reflexionar sobre las alternativas y criterios del vendedor inicial y del empresario que compra la cartera, comparándolas adicionalmente con las alternativas y criterios del comprador y vendedor en la segunda operación.Starting at €8.20
-
Genzyme and Relational Investors: Science and Business Collide?
Eades, Kenneth M.; Matos, Pedro; Green, RickCase DARDEN-F-1660-EFinanceThe chairman and CEO of the Genzyme Corporation, one of the country’s top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.Starting at €8.20
-
Servicios de programación avanzada (SPA)
Olaya Estefan, E.; Calero Castro, M.Case IIST-ASNI-19Decision AnalysisEl caso nos describe el momento en el que un emprendedor crea una empresa y cómo ésta va evolucionando a lo largo de los años. Se realiza una breve descripción de las características del emprendedor, así como de la evolución del negocio de la empresa. A pesar de que, a primera vista, pueda parecer que la empresa va bien, en un momento dado, los estados contables reflejan pérdidas y el emprendedor no sabe cómo resolver la situación. Esto permitirá...Starting at €8.20